Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-10

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The eShunt System includes proprietary delivery componentry and the eShunt Implant, a permanent implant deployed in a minimally invasive, neurointerventional procedure. The eShunt Implant is designed to mimic the function of the arachnoid granulations by draining excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy in iNPH Shunting (PENS) Trial

NCT05081128

Idiopathic Normal Pressure Hydrocephalus (INPH)

ACTIVE_NOT_RECRUITING NA

Flow Measurements in Functional CSF Shunts and Off-Shunt Locations with a Second-Generation Thermal Device

NCT06524492

Hydrocephalus

COMPLETED

Assessment of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device in Asymptomatic Patients

NCT06410885

Hydrocephalus

NOT_YET_RECRUITING NA

Post Approval Study Protocol for the Two Level Simplify® Cervical Artificial Disc

NCT04980378

Cervical Degenerative Disc Disorder

COMPLETED

A Pilot Study of the InterCushion Disc Nucleus Prosthesis (DNP) in Patients Receiving Discectomy

NCT01652053

Disk, Herniated

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, non-randomized, open-label, single-center, pilot study in subjects with normal pressure hydrocephalus for whom a traditional CSF shunt implant is indicated.

Up to 30 subjects will receive the eShunt Implant at one investigational site. Subjects will return for five follow-up visits in the first year and then continue to attend visits every six months for five years post-implantation.

The study objectives are to demonstrate safety of the eShunt Procedure, as well as demonstrate safety and efficacy of the eShunt Implant in a small sample of patients.

Subjects will be followed long-term; primary analysis results will be used to support additional studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hydrocephalus, Normal Pressure Hydrocephalus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

The Treatment Arm receives the eShunt Implant.

Group Type EXPERIMENTAL

eShunt Implant

Intervention Type DEVICE

The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eShunt Implant

The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients 65-85 years old and traditional CSF shunt placement is indicated based upon a diagnostic NPH evaluation
2. Patient is able and willing to provide written informed consent
3. History or evidence of gait impairment duration ≥6 months
4. Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:

1. Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans Index \>0.3) and the absence of severe hippocampal atrophy
2. Pre-procedure spinal tap test with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%
3. CSF opening pressure ≥10 cmH2O
4. Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
5. Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
6. Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC

Exclusion Criteria

1. Unable to walk 10 meters (33 feet) with or without an assistive device
2. Conditions impairing gait that are considered to be unrelated to hydrocephalus
3. Signs or symptoms of obstructive hydrocephalus
4. Active systemic infection or infection detected in CSF
5. Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
6. Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
7. Occlusion or stenosis of the internal jugular vein
8. Venous distension in the neck on physical exam
9. Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
10. History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
11. Stroke or transient ischemic attack within 180 days of eShunt Procedure
12. Presence of a deep vein thrombosis superior to the popliteal vein
13. International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
14. Presence of a posterior fossa tumor or mass
15. Life expectancy \< 1 year
16. Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up
17. Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation
18. Pregnant or planning to become pregnant
19. Unwilling or unable to comply with follow-up requirements

Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No